One of Europe’s leading CMOs, Aesica, has announced a key addition to its commercial team as it looks to strengthen its position in North America.

Dr Emma Mickley has been promoted from her role as Director of Business Development into the newly created position of Vice President of Corporate Business Development. Emma will be based in San Diego, California, and will support the company in growing its share of the North American contract manufacturing market.

Speaking about her promotion, she said: “This is an exciting time to be representing Aesica in North America. This region is a key strategic priority for us for the forseeable future and we are 100 per cent committed to shaping and positioning our business to meet the needs of mid-size and emerging pharma in Canada and The States”.

“The fact that genuine pharmaceutical innovation is now increasingly challenging has led big pharma to partner with small and mid size companies in developing NCEs. Taking advantage of the limited window of patent exclusivity has never been more critical, and this is where we come in”.

“Accelerating speed to market is our strength, and as an integrated CMO we offer customers in North America a fast track from development to clinical trials and onwards to market. Where we really excel is in helping emerging and mid size pharma companies get their products to clinical trials fast, before they pass the baton to big pharma, who we work with to drive formulations through to scale-up stage.”


Emma will support the company’s plans to extend its manufacturing base to cater to the North American market and capitalize on its strong core of strategic accounts within mid-sized and emerging pharma companies. Emma’s role will be central to the success of Aesica in the region, as the company expands to become the pharma industry’s partner of choice for the development and manufacture of APIs and formulated products.

Dr. Alan Raymond, Sales and Marketing Director, Aesica Pharmaceuticals, said: “I am delighted to announce Emma’s appointment into this new senior role. Expanding our presence in North America is absolutely vital to our growth on a global scale, and this position is key to us achieving that goal. Emma’s contribution will play no small part in helping us achieve our ambitions to become a trusted partner to the most innovative and respected names in pharma.”

With Emma on board to oversee the needs of the North American market, Aesica will offer the pharma sector a single point of contact across the key stages of drug development. Its integrated service includes API scale up, formulation development, manufacture of CT supplies to commercial scale and final dosage form manufacture.

  • News
  • Case Studies
  • Pages
  • Blogs
  • Locations
  • Experts